Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma
Abstract
Tumor immune microenvironment (TIME) and cancer antigen expression, key factors for the development of immunotherapies, are usually based on the data from primary tumors due to availability of tissue for analysis; data from metastatic sites and their concordance with primary tumor are lacking. Although of the same origin from primary tumor, organ-specific differences in the TIME in metastases may contribute to discordant responses to immune checkpoint inhibitor agents. In immunologically ‘cold’ tumors, cancer antigen-targeted chimeric antigen receptor (CAR) T-cell therapy can promote tumor-infiltrating lymphocytes; however, data on distribution and intensity of cancer antigen expression in primary tumor and matched metastases are unavailable.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2023
- Source ID
- 10.1136/jitc-2022-006609
Entities
People
- Alexander J Byun
- Carlos Thomas
- David R Jones
- David Restle
- Jennie K. Choe
- Joseph Dux
- Kay See Tan
- Kyohei Misawa
- Navin K. Chintala
- Prasad S Adusumilli
- Raj G. Vaghjiani
- Xiaoyu Li
- Yan Li
Organizations
- National Cancer Institute
- United States Department of Defense